Retatrutide News & Updates

Last updated: February 14, 2026

This page tracks every significant development in retatrutide's journey from clinical trials to (potential) FDA approval. Bookmark it — we update it as news breaks.

For background on the drug itself, see What Is Retatrutide (GLP-3)?. For a full trial tracker, see Clinical Trials & Results.

Upcoming Events to Watch

These are the dates and milestones most likely to generate retatrutide news in 2026.

2026

February 4 — Eli Lilly Q4 2025 Earnings: Retatrutide Filing Planned for 2026

Eli Lilly reported Q4 2025 revenue of $19.3 billion (+43% YoY) and provided major retatrutide updates on the earnings call:

• Lilly confirmed the core TRIUMPH program results will be submitted in 2026 to support regulatory applications for obesity, obstructive sleep apnea, and knee osteoarthritis
• Six additional Phase 3 trials for retatrutide expected to read out in 2026, including the pivotal TRIUMPH obesity program and the TRANSCEND type 2 diabetes program
• Management reiterated that in patients with baseline BMI >= 35 (84% of the TRIUMPH-4 trial), discontinuation rates were consistent with other injectable incretins
• Dysesthesia events were characterized as "generally mild and rarely led to treatment discontinuation"
• 2026 revenue guidance: $80-83 billion (~25% growth)

Also noted: orforglipron (Lilly's oral GLP-1) has been submitted for approval in the U.S. and 40+ countries, with U.S. approval expected Q2 2026. This is relevant because orforglipron and retatrutide represent Lilly's two-pronged next-generation obesity strategy — oral and injectable.

Sources: Lilly press release · Motley Fool earnings transcript

January 30 — Lilly Announces $3.5 Billion Pennsylvania Plant for Retatrutide Production

Eli Lilly announced a $3.5 billion injectable medicine and device manufacturing facility in Fogelsville, Pennsylvania (Lehigh Valley). This is the fourth new U.S. plant in Lilly's expansion series and will specifically produce next-generation obesity injections including retatrutide.

• 850 permanent jobs, 2,000 construction jobs
• Construction starts 2026, operational by 2031
• Brings total U.S. manufacturing commitments to over $50 billion since 2020

Source: Lilly press release

January 2026 — TRIUMPH Trial Design Paper Published

The formal design paper for the TRIUMPH Phase 3 program was published in Diabetes, Obesity and Metabolism (Volume 28, Issue 1, pages 83-93). Key details revealed:

• TRIUMPH-1 and TRIUMPH-2 are basket trials with nested obstructive sleep apnea and osteoarthritis protocols
• TRIUMPH-3 evaluates weight management in a cardiovascular disease population
• Doses being tested: 4 mg (maintenance), 9 mg, and 12 mg
• Total enrollment across TRIUMPH: >5,800 participants

Source: Giblin et al., Diabetes, Obesity and Metabolism 2026 · PubMed

2025

December 11 — TRIUMPH-4 Phase 3 Results: 28.7% Weight Loss (First Phase 3 Readout)

The defining retatrutide event of 2025. Eli Lilly announced topline results from TRIUMPH-4, the first Phase 3 trial to report data.

Weight loss (completers):

Weight loss (all participants, intent-to-treat):

Osteoarthritis outcomes: Up to 75.8% pain reduction (WOMAC score). 14.1% of participants on 9 mg were completely pain-free vs. 4.2% on placebo.

Cardiovascular markers: Non-HDL cholesterol, triglycerides, and hsCRP all improved. Systolic blood pressure reduced by 14.0 mmHg at 12 mg.

Safety signals:

• Discontinuation due to adverse events: 12.2% (9 mg), 18.2% (12 mg) vs. 4.0% (placebo)
• In patients with BMI >= 35 (84% of trial): discontinuation rates were 8.8% (9 mg), 12.1% (12 mg) vs. 4.8% (placebo) — more consistent with other incretins
• Dysesthesia: 8.8% (9 mg), 20.9% (12 mg) vs. 0.7% (placebo) — a new safety signal not seen in Phase 2
• Some discontinuations attributed to "perceived excessive weight loss"
• Common GI side effects: nausea (38-43%), diarrhea (33-35%), constipation (22-25%), vomiting (~20%)

Media coverage was extensive: ABC News ("Triple G"), NBC/Today Show, CNBC, STAT News, BioSpace, Fierce Biotech, BioPharma Dive all covered the results.

Analyst reactions:

• Daiwa upgraded LLY to Buy, raised price target to $1,230 from $940
• Bank of America maintained Buy, adjusted target to $1,268
• BMO flagged the dysesthesia signal as worth monitoring in future readouts

Sources: Lilly press release · STAT News · CNBC · BioSpace

December 9 — Lilly Announces $6 Billion Alabama Manufacturing Facility

Two days before the TRIUMPH-4 data release, Lilly announced a $6 billion active pharmaceutical ingredient facility in Huntsville, Alabama — the largest initial investment in Alabama state history. The facility will produce small molecule synthetic and peptide medicines relevant to the retatrutide supply chain.

Source: Lilly press release

November 2025 — Clarivate Names Retatrutide a "Drug to Watch" with $30B Revenue Projection

Clarivate's annual "Drugs to Watch" report named retatrutide among 11 standout pipeline drugs of the next decade. The projection: $30 billion in 2031 revenue ($10B obesity + $20B diabetes) — the highest of any drug on the list.

Sources: Clarivate press release · PharmExec · Fierce Pharma

October 30 — Q3 2025 Earnings: Seven Phase 3 Readouts Confirmed for 2026

Lilly reported Q3 2025 revenue of $17.6 billion (+54% YoY). Regarding retatrutide:

• New Phase 3 trials initiated for chronic low back pain and overweight/obesity
• Seven Phase 3 readouts confirmed as expected in 2026
• R&D expenses of $3.47 billion (+27%) reflect the scale of the pipeline

Source: Lilly press release

June 22 — ADA 2025: Preclinical Comparison of Semaglutide, Tirzepatide, and Retatrutide

At the ADA 85th Scientific Sessions, a poster presentation compared the metabolic effects of semaglutide, tirzepatide, and retatrutide in a monogenic mouse model of obesity. This preclinical study added to the scientific understanding of retatrutide's differentiated triple-agonist mechanism.

Source: Lilly ADA presentations announcement

June 2025 — Review Article: "Retatrutide — A Game Changer in Obesity Pharmacotherapy"

A comprehensive review by Katsi et al. was published in Biomolecules, summarizing retatrutide's mechanism, preclinical superiority, and clinical trial results including dose-dependent weight loss, HbA1c reductions, and liver fat improvements.

Source: Katsi et al., Biomolecules 2025

May 7 — Court Upholds FDA on Tirzepatide Compounding (Sets Precedent for Retatrutide)

The U.S. District Court for the Northern District of Texas upheld the FDA's decision to remove tirzepatide from the drug shortage list, rejecting the Outsourcing Facilities Association's challenge. This ruling solidifies the regulatory framework that will govern retatrutide at launch — compounding pharmacies will not be able to produce copies.

Source: McDermott Will & Emery

February 26 — Lilly Announces $27 Billion U.S. Manufacturing Investment

Lilly announced plans to invest $27 billion across four new U.S. manufacturing sites. One plant will specifically help produce retatrutide. Total U.S. manufacturing commitments now exceed $50 billion since 2020.

Sources: CNBC · STAT News

February 21 — FDA Removes Semaglutide from Drug Shortage List

The FDA revised semaglutide's shortage categorization to "resolved," triggering the wind-down of compounding pharmacy access. In the same announcement, the FDA explicitly noted that retatrutide and cagrilintide are NOT components of FDA-approved drugs and cannot be used in compounding.

Source: Foley & Lardner

February 6 — Q4 2024 Earnings: Lilly Accelerates Retatrutide Timeline

During the Q4 2024 earnings call, Lilly announced it expected to release late-stage data on retatrutide in 2025 — several months earlier than previously expected. The company confirmed TRIUMPH-4 results would be available later that year.

Source: CNBC · Motley Fool earnings transcript

2024

June-July — MASLD Phase 2 Results Published in Nature Medicine

The retatrutide Phase 2a MASLD sub-study was published in Nature Medicine, showing liver fat reductions of 81-86% at higher doses. Normal liver fat (<5%) was achieved by 86% of participants on 12 mg. These remain the most current peer-reviewed liver fat data for retatrutide.

Source: Nature Medicine 2024

2023

• June 2023 — Phase 2 obesity results (24.2% weight loss at 48 weeks) published in NEJM
• 2023 — Phase 2 type 2 diabetes results published in The Lancet
• 2023 — TRIUMPH Phase 3 program launched

2022

• Phase 1 results published in The Lancet

Related Pages

• What Is Retatrutide (GLP-3)? — How the triple agonist works
• Clinical Trials & Results — Detailed TRIUMPH program tracker
• Retatrutide vs Mounjaro vs Ozempic — Side-by-side comparison
• Side Effects & Safety — What clinical trials have shown
• Cost & Access — Pricing, insurance, and how to get it
• FDA Approval Timeline — When retatrutide might be approved

This page is for informational purposes only and does not constitute medical advice or financial advice. Retatrutide is an investigational drug that has not been approved by the FDA. glp3.wiki is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.